Inborn Errors of Metabolism Medication
- Author: Debra L Weiner, MD, PhD; Chief Editor: Stephen Kemp, MD, PhD more...
Emergency medications for inborn errors of metabolism (IEMs) in infants and children include drugs to eliminate toxic metabolites and/or amino acids and enzyme cofactors to compensate for metabolic deficiencies. These and other drugs may be required to maintain and treat the underlying IEM. Some IEMs are treated with replacement enzymes that are FDA approved, designated as orphan drugs, or investigational.
Helpful Web sites for finding information on orphan drug designation include the following:
- National Organization for Rare Disorders (NORD) (lists more than 1000 rare diseases)
- United States FDA's Other Sources of Rare Disease/Orphan Product Information (list of Web sites that provide information on rare diseases and orphan drugs)
Treatment of hyperammonemia; enhances elimination of nitrogen. This drug is FDA approved for treatment of hyperammonemia due to urea cycle defects and is available only from a specialty wholesaler, Ucyclyd Pharma (888-829-2593). For more information, see Ammonul prescribing information.
Indicated for acute hyperammonemic and associated encephalopathy due to urea cycle defects. For ammonia levels >500-600 mcg/dL, hemodialysis is the preferred treatment; however, sodium phenylacetate and sodium benzoate should be considered if dialysis cannot be initiated immediately. Benzoate combines with glycine to form hippurate, which is excreted in urine. One mol of benzoate removes 1 mol of nitrogen. Phenylacetate conjugates (via acetylation) glutamine in the liver and kidneys to form phenylacetylglutamine, which is excreted by the kidneys. The nitrogen content of phenylacetylglutamine per mole is identical to that of urea (2 mol of nitrogen). Ammonul should be administered with arginine-HCL for carbamyl phosphate synthetase (CPS), ornithine transcarbamylase (OTC), argininosuccinate synthetase (ASS), or argininosuccinate lyase (ASL) deficiencies and should not be given for arginase deficiency. Approved as adjunctive treatment of acute hyperammonemia associated with encephalopathy caused by urea cycle enzyme deficiencies. Preparation contains 100 mg/mL each of sodium phenylacetate and sodium benzoate and comes in 50-mL vials. Must dilute IV dose in at least 25 mL/kg of dextrose 10% up to 600 mL. Do not mix directly with other medications, but it may be piggybacked. Give in addition to daily fluid requirement but decrease maintenance fluid by volume of Ammonul given.
Essential amino acid used for certain urea cycle defects.
Enhances production of ornithine, which facilitates incorporation of waste nitrogen into the formation of citrulline and argininosuccinate. Provides 1 mol of urea plus 1 mol ornithine per mol of arginine when cleaved by arginase. Preparation is 10% arginine hydrochloride. Can be mixed with sodium phenylacetate and sodium benzoate. If administering separately, mix with sodium bicarbonate.
Enzyme cofactors are used to enhance the activity of cofactor-dependent enzymes.
Precursor of pyridoxal, which functions in the metabolism of proteins, carbohydrates, and fats. Also aids in the release of liver- and muscle-stored glycogen and in the synthesis of GABA (within the CNS) and heme. Involved in synthesis of GABA within the CNS. Indicated for seizures of unknown etiology unresponsive to conventional anticonvulsants and for seizures in patients with known pyridoxine-dependent IEM. Give undiluted or mix with other solutions. Incompatible with alkaline or oxidizing solutions and iron salts. Not to be mixed with sodium bicarbonate.
This agent is used for the treatment of primary and secondary carnitine deficiency.
An amino acid derivative, synthesized from methionine and lysine, required in energy metabolism. Can promote excretion of excess fatty acids in patients with defects that bioaccumulate acyl-CoA esters. Carnitine is indicated for most organic acidemias and is controversial for fatty acid oxidation defects.
Huang X Dr, Yang L Dr, Tong F Dr, Yang R Dr, Zhao Z Prof. Screening for inborn errors of metabolism in high-risk children: a 3-year pilot study in Zhejiang Province, China. BMC Pediatr. 2012 Feb 24. 12(1):18. [Medline].
Newborn Screening Status Report. Updated March 11, 2009. National Newborn Screening and Genetics Resource Center. Available at http://genes-r-us.uthscsa.edu/nbsdisorders.pdf.
ACGME Newborn Screening Work Group: Levy HL, Watson, MS, Metabolic Disorders: Berry G, Goodman S, Marsden D, et al. Newborn Screening Act Sheet and Confirmatory Algorithms. Newborn Screening ACT Sheets and Confirmatory Algorithms. Available at http://www.acmg.net/resources/policies/ACT/condition-analyte-links.htm. Accessed: 1/30/09.
Weiner DL. Inborn errors of metabolism. Aghababian RV, ed. Emergency medicine: the core curriculum. Philadelphia: Lippincott-Raven; 1999. 707.
Stockler S, Moeslinger D, Herle M, Wimmer B, Ipsiroglu OS. Cultural aspects in the management of inborn errors of metabolism. J Inherit Metab Dis. 2012 Feb 23. [Medline].
Dickson PI, Tolar J. The individual (single patient) IND for inborn errors of metabolism. Mol Genet Metab. 2014 Oct 13. [Medline].
Illsinger S, Das AM. Impact of selected inborn errors of metabolism on prenatal and neonatal development. IUBMB Life. 2010 Jun. 62(6):403-13. [Medline].
Acute Illness Protocols. New England Consortium of Metabolic Programs at Children's Hospital Boston. Available at http://www.childrenshospital.org/newenglandconsortium/NBS/Emergency_Protocols.html. Accessed: 1/30/09.
Arn PH, Valle DL, Brusilow SW. Inborn errors of metabolism: not rare, not hopeless. Contemp Pediatr. 1988. 5:47-63.
Burton BK. Inborn errors of metabolism in infancy: a guide to diagnosis. Pediatrics. 1998 Dec. 102(6):E69. [Medline].
Calvo M, Artuch R, Macia E, et al. Diagnostic approach to inborn errors of metabolism in an emergency unit. Pediatr Emerg Care. 2000 Dec. 16(6):405-8. [Medline].
Chace DH, Kalas TA, Naylor EW. Use of tandem mass spectrometry for multianalyte screening of dried blood specimens from newborns. Clin Chem. 2003 Nov. 49(11):1797-817. [Medline].
Chow SL, Gandhi V, Krywawych S, Clayton PT, Leonard JV, Morris AA. The significance of a high plasma ammonia value. Arch Dis Child. 2004 Jun. 89(6):585-6. [Medline].
Enns GM, Packman S. Diagnosing inborn errors of metabolism in the newborn: clinical features. Neo Reviews. 2001. 2000:e183-90.
Fernandes J, Saudubray JM, Van den Berghe G. Inborn Metabolic Diseases: Diagnosis and Treatment. 3rd ed. Springer-Verlag: 2000.
Funded by NIH. PI: Pagon RA. GeneReviews, Laboratory Directory, Clinic Directory, Educational Materials. GeneTests. Available at http://bit.ly/eOUcdy. Accessed: 1/30/09.
Garganta CL, Smith WE. Metabolic evaluation of the sick neonate. Semin Perinatol. 2005 Jun. 29(3):164-72. [Medline].
Goodman SI. Inherited metabolic disease in the newborn: approach to diagnosis and treatment. Adv Pediatr. 1986. 33:197-223. [Medline].
Hoffman GF, Nyhan WL, Zschocke J. Inherited Metabolic Diseases. Philadelphia: Lippincott Williams & Wilkins; 2002.
James PM, Levy HL. The clinical aspects of newborn screening: importance of newborn screening follow-up. Ment Retard Dev Disabil Res Rev. 2006. 12(4):246-54. [Medline].
Kwon KT, Tsai VW. Metabolic emergencies. Emerg Med Clin North Am. 2007 Nov. 25(4):1041-60, vi. [Medline].
Marsden D, Larson C, Levy HL. Newborn screening for metabolic disorders. J Pediatr. 2006 May. 148(5):577-584. [Medline].
McKusik VA. OMIM Online Mendelian Inheritance in Man [database online]. McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine (Bethesda, MD). Available at http://www.ncbi.nlm.nih.gov/omim.
Nasser M, Javaheri H, Fedorowicz Z, Noorani Z. Carnitine supplementation for inborn errors of metabolism. Cochrane Database Syst Rev. 2012 Feb 15. 2:CD006659. [Medline].
Ward JC. Inborn errors of metabolism of acute onset in infancy. Pediatr Rev. 1990 Jan. 11(7):205-16. [Medline].
Weinstein DA, Butte AJ, Raymond K. High incidence of unrecognized metabolic and endocrinologic disorders in acutely ill children with previously unrecognized hypoglycemia. Pediatr Res. 2001. 49:103A#578.
|Poor feeding, vomiting, failure to thrive||X||+||++||+||X||X||+||+||+|
|Dysmorphic features and/or skeletal or organ malformations||X||X||-||-||X||X||+||X||X|
|Abnormal hair and/or dermatitis||-||X||X||-||-||-||-||-||-|
|Cardiomegaly and/or arrhythmias||-||X||-||-||X||X||+||-||X|
|Hepatosplenomegaly and/or splenomegaly||X||+||+||+||+||+||+||X||X|
|Developmental delay +/- neuroregression||+||+||+||X||X||X||++||+||+|
|Lethargy or coma||X||++||++||+||X||++||-||-||X|
|Hypotonia or hypertonia||+||+||+||+||X||+||X||+||X|
|Primary metabolic acidosis||X||++||+||+||X||+||-||-||X|
|Primary respiratory alkalosis||-||-||+||-||-||-||-||-||-|
|*Within disease categories, not all diseases have all findings. For disorders with episodic decompensation, clinical and laboratory findings may be present only during acute crisis. For progressive disorders, findings may not be present early in the course of disease.|
AA = Amino acidopathy
OA = Organic acidopathy
UCD = Urea cycle defect
CD = Carbohydrate disorder
GSD = Glycogen storage disorder
FAD = Fatty acid oxidation defect
LSD = Lysosomal storage disease
PD = Peroxisomal disorder
MD = Mitochondrial disorder
++ = Always present
+ = Usually present
X = Sometimes present
- = Absent
H = Inappropriately high
L = Inappropriately low
A = Appropriate